Cargando…

Normatização de programas de acesso expandido e uso compassivo de medicamentos na América do Sul

OBJECTIVE. To describe and compare the regulatory framework governing policies on rapid/alternative access to medicines (expanded access and compassionate use) in South American countries. METHOD. An exploratory descriptive study with analysis of documents was performed. In addition to a literature...

Descripción completa

Detalles Bibliográficos
Autores principales: Mosegui, Gabriela Bittencourt Gonzalez, Antoñanzas, Fernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Organización Panamericana de la Salud 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611211/
https://www.ncbi.nlm.nih.gov/pubmed/31363359
http://dx.doi.org/10.26633/RPSP.2019.57
Descripción
Sumario:OBJECTIVE. To describe and compare the regulatory framework governing policies on rapid/alternative access to medicines (expanded access and compassionate use) in South American countries. METHOD. An exploratory descriptive study with analysis of documents was performed. In addition to a literature review, official rules issued by regulatory agencies were reviewed if available. Information was collected on how countries define the concepts of expanded access and compassionate use, clinical phase in which the medicine becomes available for these alternative uses, and role of physicians and sponsors. RESULTS. Argentina, Brazil, Chile, Peru, and Uruguay were included in the study. The information obtained revealed that the regulatory scenario is more structured in Argentina and Brazil than in the other countries. In Chile, rules on expanded access and compassionate use are available, however without an explicit definition of these concepts. In Peru and Uruguay, important definitions are missing regarding expanded access. The search did not reveal any databases with information on expanded access and compassionate use programs, supporting the notion that empirical data to evaluate the results of these policies are lacking. CONCLUSIONS. All the countries analyzed have a regulatory framework that contemplates rapid/alternative access to medicines by patients at risk. However, databases and transparent information are lacking, preventing a snapshot of the medicines covered and patients benefiting from alternative access programs and assessments of these policies in South America.